AFP-L3% (Alpha-Fetoprotein-L3 Percent) is a specialized blood test that measures the percentage of a specific subtype of alpha-fetoprotein (AFP) in the bloodstream. AFP is a protein normally produced by the liver and yolk sac during fetal development. In adults, elevated AFP levels can be a sign of liver disease or cancer, particularly hepatocellular carcinoma (HCC), the most common type of primary liver cancer. AFP exists in different forms, and AFP-L3 is a glycosylated variant that is more specifically associated with malignant liver tumors. The AFP-L3% refers to the proportion of total AFP that is the L3 subtype, offering more precise insight into the risk or presence of liver cancer. Why is AFP-L3% tested? This marker is most commonly used in conjunction with total AFP levels to: Aid in early detection of hepatocellular carcinoma (HCC) Distinguish between benign liver conditions and malignant tumors Monitor high-risk patients, such as those with chronic hepatitis B or C, or cirrhosis Assess cancer progression or recurrence in individuals previously diagnosed with liver cancer How is AFP-L3% interpreted? Low or undetectable AFP-L3%: Generally suggests a lower risk of liver cancer, especially when total AFP is normal. Elevated AFP-L3% (typically >10%): May indicate a higher risk or presence of hepatocellular carcinoma, even if total AFP is not markedly elevated. A rising AFP-L3% over time can be an early sign of cancer development. Important: AFP-L3% should not be used as a standalone diagnostic tool. It is most effective when interpreted alongside imaging studies (like liver ultrasound or MRI), total AFP levels, and clinical history. Who should get tested? AFP-L3% is typically recommended for: Individuals with chronic liver disease (especially hepatitis B or C) People with cirrhosis Those being monitored for liver cancer recurrence after treatment Individuals with elevated total AFP but inconclusive imaging results In summary: AFP-L3%, Serum is a highly specific biomarker used to help detect and monitor liver cancer risk, especially in people with existing liver conditions. When combined with total AFP and imaging, it provides a more accurate picture of liver health and helps guide further diagnostic or treatment decisions.
Tumor Markers
Tumor markers are substances measured in blood, urine, or tissue that can provide information about cancer. Some are produced by cancer cells; others are produced by normal cells and can also increase in noncancerous conditions. Examples include PSA, CA 125, CEA, AFP, and HE4.
What are tumor marker tests used for?
Depending on the marker and clinical setting, these tests can help:
-
Support a diagnosis alongside imaging, biopsy, and other findings.
-
Guide treatment selection.
-
Monitor response to treatment.
-
Look for signs of recurrence or progression.
-
Provide information about the likely course of a diagnosed cancer.
Not every marker serves every purpose. A falling level may support a treatment response, while a rising level may prompt further evaluation. Neither change establishes what is happening on its own.
Does an elevated tumor marker mean cancer?
An elevated tumor marker does not automatically mean cancer, and a normal result does not rule it out. Benign conditions can affect results, and some cancers do not produce elevated markers.
Interpretation depends on the specific test, the laboratory’s reference range, previous results, and the reason testing was ordered. During cancer follow-up, changes over time may be more informative than a single measurement.
Can tumor markers be used for cancer screening?
A test used to monitor diagnosed cancer is not automatically suitable for screening people without symptoms. Many circulating tumor markers perform poorly as general screening tests because they can miss cancers or give elevated results in people who do not have cancer.
Some markers have specific screening roles. For example, PSA testing may be considered after an individual discussion of prostate cancer risk, potential benefits, and possible harms. These harms include false-positive results, unnecessary investigations, and finding cancers that would never have caused symptoms.
Use each marker’s individual page to understand its purpose and limitations. Tumor marker testing should complement the appropriate clinical assessment and recommended cancer screening.
Biomarkers in this category
26 biomarkers · optimal ranges shown
a tumor marker test
The CA 125 test measures the amount of the protein CA 125 (=cancer antigen 125) in your blood.
to screen, diagnose, and stage breast cancer
a type of tumor marker
The cancer antigen 27.29 test (CA 27.29) is a blood test that measures the levels of glycoprotein produced by the mucin-1 (MUC1) gene. The level of CA 27.29, also known as 27.29, is used as a tumor marker to measure the activity of the disease in patients with breast cancer. It’s one of several types of tumor markers used for breast cancer and is most commonly used in advanced breast cancer, as opposed to early-stage breast cancer. What is a CA 27.29 test used for? What is the difference between CA 15-3 and CA 27.29? Another type of tumor marker, CA 15-3, also measures a similar antigen, but doctors generally choose one test or the other. They aren’t often used interchangeably for the same patient. CA 27.29 levels and normal range After a CA 27.29 test, doctors interpret the test results, which are measured in units per milliliter (U/mL). The normal range of CA 27.29 is 0 to 38 U/mL. If a patient’s CA 27.29 is elevated, this may indicate that further tests are needed. However, every patient’s situation is unique, so it’s important for patients to speak to their doctor about specific CA 27.29 results and what they mean. While CA 27.29 levels may be elevated due to metastatic breast cancer, they may also be raised by other health conditions, including: - Other cancer types - Localized breast cancer - Some noncancerous conditions Ongoing cancer treatment may also impact CA 27.29 levels, since chemotherapy may increase levels in the body immediately after treatment. For this reason, doctors may wait to administer a CA 27.29 test until after the patient has finished a round of active treatment. While it’s normal for patients to feel anxious or worried when waiting for results, CA 27.29 fluctuations over time may occur, so test results are only one part of the bigger picture. Results may go up and down over time for different reasons, so careful interpretation is needed over the long term.
related to gastrointestinal and ovarian cancers
Cancer monitoring tumor marker
a protein found on the surface of B-cells
may be used to help detect neuroendocrine tumors
a tumor maker of lung cancer
Tumor marker used to help monitor epithelial ovarian cancer.
analyze and classify various blood and bone marrow disorder
Enzyme involved in tissue remodeling, linked to inflammation and cancer.
also known as gelatinase B
predominantly found in neurons and neuroendocrine cells
Total Prostate Specific Antigen (TPSA) is a serine protease produced by prostate cells, primarily used as a biomarker for the screening and monitoring of prostate cancer. While elevated TPSA levels can indicate the presence of prostate cancer, they can also arise from benign conditions such as benign prostatic hyperplasia (BPH) and prostatitis. The TPSA test measures the total amount of PSA in the blood, which includes both free and protein-bound forms. Although TPSA is a valuable tool in early detection and management of prostate cancer, its specificity is limited, as elevated levels can occur in non-cancerous conditions. Therefore, healthcare providers often use additional tests, such as the free-to-total PSA ratio, to improve diagnostic accuracy and differentiate between benign and malignant prostate conditions.
Prostate cancer test
Prostate cancer enzyme marker
Prostate cancer risk refinement
S100B is a tumour marker used to monitor malignant melanoma and assess brain injury. Normal: 0–0.1 µg/L. Elevated levels may indicate disease progression or recurrence. HealthMatters.
Total Prostate Specific Antigen (TPSA) is a serine protease produced by prostate cells, primarily used as a biomarker for the screening and monitoring of prostate cancer. While elevated TPSA levels can indicate the presence of prostate cancer, they can also arise from benign conditions such as benign prostatic hyperplasia (BPH) and prostatitis. The TPSA test measures the total amount of PSA in the blood, which includes both free and protein-bound forms. Although TPSA is a valuable tool in early detection and management of prostate cancer, its specificity is limited, as elevated levels can occur in non-cancerous conditions. Therefore, healthcare providers often use additional tests, such as the free-to-total PSA ratio, to improve diagnostic accuracy and differentiate between benign and malignant prostate conditions.
Understanding the Highly Sensitive Tumor Necrosis Factor-Alpha (TNF-α) Test Tumor Necrosis Factor-Alpha (TNF-α) is a critical biomarker used in medical diagnostics and research, known for its role in regulating inflammation and the immune system. A highly sensitive TNF-α test provides accurate detection of this cytokine, aiding in the diagnosis and management of various health conditions. What Is TNF-α? TNF-α is a cytokine primarily produced by activated macrophages, though other cells can also secrete it. It plays a central role in: Promoting inflammation Coordinating immune responses Inducing programmed cell death (apoptosis) Why Is TNF-α Important? Clinical Applications Diagnosing and Monitoring Diseases TNF-α levels are useful for identifying and managing conditions such as: Autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease) Chronic inflammatory conditions Infections, including sepsis Treatment Monitoring The test helps: Assess disease activity in chronic inflammatory disorders Monitor the effectiveness of anti-TNF therapies Guide treatment decisions, particularly for patients using TNF inhibitors Key Features of the Highly Sensitive TNF-α Test Sample Type: Blood (serum) Patient Preparation: No special preparation required Sensitivity: Detects lower concentrations of TNF-α for more precise results Interpreting TNF-α Levels Understanding test results requires consideration of the patient's overall health and symptoms: Elevated Levels: Suggest active inflammation and may indicate more severe disease activity. Extremely High Levels: In cases like sepsis, this may signal a life-threatening condition. Persistently High Levels in Therapy: Could indicate ineffective treatment with TNF inhibitors. Research Applications of TNF-α TNF-α remains a key focus in medical research for: Developing new therapies for autoimmune diseases Exploring anticancer potential Understanding inflammation and immune system mechanisms Conclusion The highly sensitive TNF-α test is a powerful tool in both clinical and research settings. It provides detailed insights into inflammatory and immune-related conditions, helping healthcare providers make informed decisions about diagnosis and treatment.